Natco Pharma Launches Generic Pomalyst in US; Eyes $3.2Bn Market with Exclusivity

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorSimar Singh|Published at:
Natco Pharma Launches Generic Pomalyst in US; Eyes $3.2Bn Market with Exclusivity
Overview

Natco Pharma, through its partner Breckenridge Pharmaceutical, Inc., has launched Pomalidomide Capsules, a generic version of Pomalyst®, in the U.S. market. This move targets a segment with estimated branded sales of USD 3.2 billion and grants Natco an anticipated 180 days of shared exclusivity, strengthening its oncology and specialty drug portfolio in a key global market.

Natco Pharma Launches Generic Pomalyst in US, Targeting $3.2 Billion Market

USD 3.2 billion in U.S. sales for the branded Pomalyst® in the 12 months ending September 2025.
Natco Pharma anticipates 180 days of shared exclusivity following this launch.

Reader Takeaway: U.S. market entry with exclusivity for $3.2Bn drug; pricing and competition key.

What just happened (today’s filing)

Natco Pharma, in collaboration with its partner Breckenridge Pharmaceutical, Inc., has officially launched Pomalidomide Capsules, the generic version of Pomalyst®, in the United States.

This signifies a major step for the Indian pharmaceutical company, as it enters a lucrative segment of the U.S. market.

The drug is indicated for treating multiple myeloma and Kaposi sarcoma, addressing critical patient needs in these therapeutic areas.

Why this matters

The launch targets a U.S. market segment where the branded Pomalyst® generated an estimated USD 3.2 billion in sales for the 12 months ending September 2025.

Natco expects to benefit from 180 days of shared exclusivity, a crucial period for establishing market presence and recouping investment.

This development significantly strengthens Natco's oncology and specialty drug portfolio within the vital U.S. market, aligning with its mission to enhance access to specialty medicines globally.

The backstory (grounded)

Natco Pharma and Breckenridge Pharmaceutical, Inc. had previously received final USFDA approval for Pomalidomide Capsules in November 2020, following a settlement of patent litigation with Celgene (now Bristol-Myers Squibb).

While Natco and Breckenridge were previously named defendants in an antitrust lawsuit concerning Pomalidomide (POMALYST) capsules, they were voluntarily dismissed from the case in December 2023, with all claims against them dismissed.

The company has a history of launching complex generics in regulated markets, focusing on oncology and specialty pharmaceuticals.

What changes now

  • Enhanced U.S. Market Presence: Natco significantly boosts its footprint in the U.S. pharmaceutical landscape, particularly in the high-value oncology segment.
  • Revenue Potential: The launch offers substantial revenue opportunities, leveraging the significant market size of the branded drug and the anticipated 180-day exclusivity period.
  • Portfolio Diversification: It reinforces Natco's expertise in developing and commercializing complex generic drugs, expanding its specialty portfolio.
  • Access to Medicines: The introduction of a generic version aims to improve affordability and patient access to essential treatments for multiple myeloma and Kaposi sarcoma.

Risks to watch

Natco Pharma's API manufacturing facility in Chennai received seven observations from the U.S. FDA in November 2025, which could potentially impact future product approvals and supplies to U.S. markets, although this specific launch is based on prior approvals.

Generic drug launches in the U.S. market are subject to intense competition and pricing pressures once exclusivity periods end.

Peer comparison

Natco's move mirrors the strategic focus of several Indian peers in the U.S. oncology generics space.

  • Lupin Limited recently launched its generic Dasatinib Tablets, targeting a market estimated at $930 million.
  • Dr. Reddy's Laboratories has a track record of launching generic oncology drugs like Imatinib Mesylate and Lenalidomide in the U.S..
  • Cipla has secured USFDA approvals for generic versions of cancer drugs like Abraxane and Lenalidomide, reinforcing its oncology portfolio.
  • Sun Pharmaceutical Industries is also actively launching specialty and oncology drugs in the U.S., such as Unloxcyt.

These companies are all leveraging their R&D capabilities to tap into the lucrative U.S. oncology market, which is valued at approximately $145 billion and growing at a CAGR of around 11%.

Context metrics (time-bound)

  • The U.S. market for the branded Pomalyst® (pomalidomide) recorded estimated sales of USD 3.2 billion for the 12 months ending September 2025.
  • Natco Pharma is expected to benefit from 180 days of shared exclusivity for Pomalidomide Capsules in the U.S. market.

What to track next

  • Exclusivity Performance: Monitor how Natco capitalizes on its 180-day shared exclusivity period.
  • Market Share Dynamics: Observe the uptake of Natco's generic Pomalidomide Capsules against the branded product and any other potential generics.
  • Profitability: Analyze the revenue contribution from this launch in upcoming quarterly results.
  • Regulatory Compliance: Keep an eye on any updates regarding Natco's U.S. FDA compliance, particularly concerning its API facilities.
  • Partnership Success: Assess the ongoing collaboration with Breckenridge Pharmaceutical, Inc. in the U.S. market.
  • Future Launches: Track Natco's pipeline for further oncology and specialty drug launches in key global markets.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.